Chugai Pharmaceutical : Script (including Q&A)

CHUGAI PHARMACEUTICAL CO., LTD.

Conference on FY2021.12 Financial Results

February 3, 2022

Event Summary

[Company Name]	CHUGAI PHARMACEUTICAL CO., LTD.
[Company ID]	4519-QCODE
[Event Language]	JPN
[Event Type]	Earnings Announcement
[Event Name]	Conference on FY2021.12 Financial Results
[Fiscal Period]	FY2021 Annual
[Date]	February 3, 2022
[Number of Pages]	55
[Time]	18:00 - 19:42
	(Total: 102 minutes, Presentation: 52 minutes, Q&A: 50 minutes)
[Venue]	Dial-in
[Venue Size]
[Participants]
[Number of Speakers]	5
	Osamu Okuda	President & CEO
	Toshiaki Itagaki	Executive Vice President & CFO
	Tetsuya Yamaguchi	Executive Vice President, Head of Project &
		Lifecycle Management Unit
	Shinji Hidaka	Vice President, Head of Marketing & Sales
		Div.
	Toshiya Sasai	Head of Corporate Communications Dept.
[Analyst Names]*	Fumiyoshi Sakai	Credit Suisse Securities (Japan) Limited
	Akinori Ueda	Goldman Sachs Japan Co., Ltd.
	Seiji Wakao	JPMorgan Securities Japan Co., Ltd.
	Hidemaru Yamaguchi	Citigroup Global Markets Japan Inc.
	Kazuaki Hashiguchi	Daiwa Securities Co. Ltd.
	Shinichiro Muraoka	Morgan Stanley MUFG Securities Co., Ltd.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

1

*Analysts that SCRIPTS Asia was able to identify from the audio who spoke during Q&A.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

2

Presentation

Sasai: Thank you very much for participating in today's financial results briefing for the fiscal year ended December 2021.

I'm Sasai of Corporate Communications Department, and I'll be moderating today's session. Thanks.

In order to prevent the spread of the new COVID-19 infection, today's session is being conducted online. If you connect to the URL for the webcast, which can be found at the bottom of the email invitation for the conference call, you will be able to view the presentation material and video with audio. The audio will come from the conference call system, so even when you are viewing the video at the same time, please do not disconnect the line.

The agenda for today's meeting can be found on the web page and on page three of the presentation material.

Questions will be taken collectively after all presentations have been completed. The Q&A session is scheduled to last about 30 minutes.

Mr. Okuda will now give a summary of FY2021 and the outlook for FY2022.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

3

Okuda: I am Okuda, the President of the Company. I will give you a summary of FY2021 and a forecast for FY2022.

Please refer to page five.

For the full year of 2021, revenues increased by 27.1% to JPY999.8 billion compared to the same period last year, and operating profit and net income each increased by more than 40%. For the fifth consecutive year, we achieved record-high revenues, operating profit, and net income.

Sales in the domestic market grow by 26.8%. Despite the impact of the price revision and generics, our mainstay products such as Tecentriq and Hemlibra, and new products such as Enspryng and Polivy, in addition to Ronapreve, a COVID-19 treatment that began to be delivered to the government in July last year, grew steadily.

Overseas sales increased by 26.6%. Exports of Actemra to Roche declined as expected, but the strong growth of Hemlibra made a significant contribution. Royalties and other operating profit increased 28.2%, mainly due to an increase in royalties based on the growth of overseas local sales of Hemlibra.

Together, these results exceeded our full-year forecast, which was revised upward substantially in October last year.

Support
Japan	03.4405.3160	North America	1.800.674.8375
Tollfree	0120.966.744	Email Support	[e-mail]

4